As both US and EU antitrust regulators discuss the fight against pay-for-delay agreements, seen as anticompetitive for the pharmaceuticals market, the European Commission is reporting an increased number of cases against brand name drug makers concerning the agreements. At the Reuters Euro Zone Summit, Commissioner Joaquin Almunia announced additional cases are headed towards the regulator as more than a dozen drug companies have already been under fire and encompassed under four investigations by the Commission. In outlining the Commissions’ plan of attack to combat the anticompetitive actions, which could lead to consumers paying more for drugs as generics are kept off the shelves, Almunia noted that while those who hold patents to a drug must be protected, once those patents expire, “all citizens should have the right” to access the generics and, therefore, cheaper drugs. The companies involved in the ongoing investigations were not named at the Summit.
Featured News
Italy Ends Vorwerk Antitrust Probe After Consumer Compensation Deal
Nov 19, 2026 by
CPI
Canada Wins Court Order to Advance Gap, Old Navy Advertising Probe
Nov 19, 2026 by
CPI
Russia Orders Major Retailers to Disclose Food Pricing Data in Antitrust Review
Nov 19, 2026 by
CPI
UK Court Confirms Government Demand for Access to Apple’s Encrypted Data
Nov 19, 2026 by
CPI
UK Competition Watchdog Probes Into OCS’s £3.1 Billion Mitie Deal
Nov 18, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Labor Market Collusion
Nov 19, 2026 by
CPI
From Price-Fixing to Wage-Fixing: Are Labor Markets the Next Frontier of Public and Private Competition Law Enforcement?
Nov 19, 2026 by
Giulia Rurali & Carsten Krüger
Damage Estimation and Labor Market Collusion
Nov 19, 2026 by
Louis D. Pape
Recent Developments of Labor Market Collusion in the EU: The Dialogue Between Delivery Hero and Tondela
Nov 19, 2026 by
Catarina Vieira Peres & Rita Ferreira Gomes
Enforcement in Labor Collusion and Monopsony: Trends and Challenges
Nov 19, 2026 by
Leyla Karakas & Anna Meyendorff